- Home
- ARQQ vs LRMR Comparison
ARQQ vs LRMR Comparison
Compare ARQQ & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQQ | LRMR |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.7M | 280.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARQQ | LRMR |
|---|---|---|
| Price | $16.53 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $60.00 | $16.50 |
| AVG Volume (30 Days) | 270.7K | ★ 1.1M |
| Earning Date | 12-09-2025 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,000.00 | N/A |
| Revenue This Year | $381.13 | N/A |
| Revenue Next Year | $212.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.00 | $1.61 |
| 52 Week High | $62.00 | $5.37 |
Technical Indicators
Market Signals| Indicator | ARQQ | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 29.53 | 37.07 |
| Support Level | $15.89 | $3.06 |
| Resistance Level | $17.45 | $3.40 |
| Average True Range (ATR) | 1.57 | 0.20 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 7.34 | 9.38 |
Price Performance
Historical ComparisonAbout ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.